- Home
- HMST vs BMEA Comparison
HMST vs BMEA Comparison
Compare HMST & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- BMEA
- Stock Information
- Founded
- HMST 1921
- BMEA 2017
- Country
- HMST United States
- BMEA United States
- Employees
- HMST N/A
- BMEA N/A
- Industry
- HMST Major Banks
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- BMEA Health Care
- Exchange
- HMST Nasdaq
- BMEA Nasdaq
- Market Cap
- HMST 246.0M
- BMEA 65.8M
- IPO Year
- HMST 2012
- BMEA 2021
- Fundamental
- Price
- HMST $13.09
- BMEA $1.81
- Analyst Decision
- HMST Hold
- BMEA Strong Buy
- Analyst Count
- HMST 3
- BMEA 10
- Target Price
- HMST $14.17
- BMEA $22.30
- AVG Volume (30 Days)
- HMST 67.9K
- BMEA 2.2M
- Earning Date
- HMST 07-28-2025
- BMEA 07-30-2025
- Dividend Yield
- HMST N/A
- BMEA N/A
- EPS Growth
- HMST N/A
- BMEA N/A
- EPS
- HMST N/A
- BMEA N/A
- Revenue
- HMST $78,454,000.00
- BMEA N/A
- Revenue This Year
- HMST $161.80
- BMEA N/A
- Revenue Next Year
- HMST $8.90
- BMEA N/A
- P/E Ratio
- HMST N/A
- BMEA N/A
- Revenue Growth
- HMST N/A
- BMEA N/A
- 52 Week Low
- HMST $8.41
- BMEA $1.29
- 52 Week High
- HMST $16.10
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- HMST 62.61
- BMEA 49.28
- Support Level
- HMST $13.05
- BMEA $1.58
- Resistance Level
- HMST $13.55
- BMEA $2.01
- Average True Range (ATR)
- HMST 0.35
- BMEA 0.14
- MACD
- HMST 0.03
- BMEA 0.01
- Stochastic Oscillator
- HMST 84.42
- BMEA 75.40
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.